Oruka Therapeutics (ORKA) Common Equity (2010 - 2026)

Oruka Therapeutics has reported Common Equity for 17 years, with the latest figure at $486.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 33.45% year-over-year to $486.7 million; the trailing twelve-month figure through Mar 2026 stood at $486.7 million (up 33.45% YoY), and the FY2025 full-year result was $471.9 million, up 23.47% from the prior year.
• Common Equity for Q1 2026 stood at $486.7 million, up from $471.9 million in the prior quarter.
• The five-year high for Common Equity was $486.8 million in Q3 2025, with the low at -$29.0 million in Q2 2024.
• Average Common Equity over 5 years is $186.7 million, with a median of $45.0 million recorded in 2022.
• Year-over-year, Common Equity plunged 173.86% in 2024 and soared 5266.81% in 2025.
• Tracing ORKA's Common Equity over 5 years: stood at $41.7 million in 2022, then decreased by 11.17% to $37.0 million in 2023, then jumped by 932.47% to $382.2 million in 2024, then grew by 23.47% to $471.9 million in 2025, then advanced by 3.13% to $486.7 million in 2026.
• The last three Common Equity figures came in at $486.7 million (Q1 2026), $471.9 million (Q4 2025), and $486.8 million (Q3 2025), per Business Quant data.

Peer Comparison